EVR and EPO for Liver Transplant Tolerance

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

June 1, 2030

Study Completion Date

June 1, 2030

Conditions
Liver Transplant
Interventions
DRUG

Everolimus

"The starting dose of EVR will be based on the maintenance TAC dose of the subject at study entry:~1. EVR 1 mg PO BID if TAC dose is \<=2 mg BID~2. EVR 2 mg PO BID if TAC dose is 2.5-7 mg BID~3. EVR 3 mg PO BID if TAC dose is \>7 mg BID~The dosage will be adjusted as needed to achieve and maintain EVR trough concentration of 5-8 ng/mL."

DRUG

Epoetin alfa

The dose used in this study is 10,000 units SC every 8 weeks (at study weeks 16, 24, 32, 40 and 48) for five doses

Trial Locations (3)

19104

University of Pennsylvania Medical Center, Philadelphia

60611

Northwestern University Feinberg School of Medicine, Chicago

94143

University of California San Francisco School of Medicine, San Francisco

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH